ATP synthase inhibitor for Acinetobacter baumannii

About Receptor.ai

Receptor.ai is a private, pre-revenue AI-native biotechnology company offering an end-to-end computational drug discovery platform. Its core technology is a modular, agentic AI-driven ecosystem with three distinct platforms for small molecules, peptides, and proximity inducers, each designed to tackle specific modality challenges like cryptic pocket targeting and multiparametric optimization. The company operates a platform/services business model, partnering with biopharma clients to generate novel, IP-free drug candidates, as evidenced by its published case studies, though it does not appear to have an internal therapeutic pipeline advancing through clinical trials.